甲状腺激素治疗与亚临床甲状腺功能减退症死亡率的关系:系统综述与荟萃分析
CONTEXT: Benefits of thyroid hormone therapy on mortality in adults with subclinical hypothyroidism remain undetermined. OBJECTIVE: To summarize the impact of thyroid hormone therapy on mortality in adults with subclinical hypothyroidism.…
要点
- 总体亚临床甲减成人中甲状腺激素治疗未显著降低全因或心血管死亡率。
- 年龄<65-70岁者治疗与全因及心血管死亡率降低显著相关。
- 年龄≥65-70岁者治疗未显示死亡率获益。
核心结论
- 甲状腺激素治疗对老年亚临床甲减患者死亡率无保护作用。
- 对年龄<65-70岁的成人,甲状腺激素治疗可能对死亡率有益。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase、Scopus、Web of Science和Clinicaltrials.gov至2020年4月25日。
- 比较甲状腺激素治疗与安慰剂或无治疗对全因和/或心血管死亡率的影响,采用随机效应模型。
主要发现
- 年龄≥65-70岁者,治疗与死亡率无显著关联。
临床怎么用
- 对老年亚临床甲减患者,不应仅以降低死亡率为目的常规启动甲状腺激素治疗。
- 对年龄<65-70岁的亚临床甲减成人,可考虑甲状腺激素治疗以潜在降低死亡风险,但需结合个体情况。
局限性
- 纳入研究数量有限(5项观察性研究和2项随机对照试验),证据强度受限。
- 亚组分析基于年龄分层,可能存在混杂因素。
- 总体结果异质性及观察性研究固有偏倚可能影响结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Benefits of thyroid hormone therapy on mortality in adults with subclinical hypothyroidism remain undetermined. OBJECTIVE: To summarize the impact of thyroid hormone therapy on mortality in adults with subclinical hypothyroidism. DATA SOURCES: PubMed, Embase, Scopus, Web of Science, and Clinicaltrials.gov from inception until April 25, 2020. STUDY SELECTION: Studies comparing the effect of thyroid hormone therapy with that of placebo or no therapy in adults with subclinical hypothyroidism on all-cause and/or cardiovascular mortality. DATA EXTRACTION: Two reviewers independently extracted data and performed quality assessments. Random-effects models for meta-analyses were used. DATA SYNTHESIS: Five observational studies and 2 randomized controlled trials with 21 055 adults were included. Overall, thyroid hormone therapy was not significantly associated with all-cause (pooled relative risk [RR] = 0.95, 95% confidence interval [CI]: 0.75-1.22, P = .704) or cardiovascular (pooled RR = 0.99, 95% CI: 0.82-1.20, P = .946) mortality. Subgroup analyses revealed that in younger adults (aged <65-70 years), thyroid hormone therapy was significantly associated with a lower all-cause (pooled RR = 0.50, 95% CI: 0.29-0.85, P = .011) and cardiovascular (pooled RR = 0.54, 95% CI: 0.37-0.80, P = .002) mortality. However, no significant association between thyroid hormone therapy and mortality was observed in older adults (aged ≥65-70 years). CONCLUSIONS: Use of thyroid hormone therapy does not provide protective effects on mortality in older adults with subclinical hypothyroidism. However, thyroid hormone therapy for subclinical hypothyroidism may show benefits on morality in adults aged <65 to 70 years.
引用
- Peng CC, Huang HK, Wu BB, et al. Association of Thyroid Hormone Therapy with Mortality in Subclinical Hypothyroidism: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2021. PMID: 33107557. doi:10.1210/clinem/dgaa777
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。